Elevai Labs (ELAB) Stock Price, News & Analysis

Company Overview

Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.

Key Stats

• Today's Range: $2.08 to $2.23
• 50-Day Range: $2.08 to $4.55
• 52-Week Range: $1.95 to $939.96
• Volume: 27,367 shs
• Average Volume: 259,194 shs
• Market Capitalization: $2.96 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ELAB Stock Analysis - Frequently Asked Questions

How have ELAB shares performed this year?

Elevai Labs' stock was trading at $16.03 at the start of the year. Since then, ELAB shares have decreased by 86.6% and is now trading at $2.15.
View the best growth stocks for 2025 here.

How were Elevai Labs' earnings last quarter?

Elevai Labs, Inc. (NASDAQ:ELAB) released its quarterly earnings results on Wednesday, May, 14th. The company reported ($2.90) earnings per share (EPS) for the quarter. Elevai Labs had a negative trailing twelve-month return on equity of 124.93% and a negative net margin of 223.41%.

When did Elevai Labs' stock split?

Elevai Labs shares reverse split on the morning of Monday, March 10th 2025. A 1-7 reverse split was announced. The number of shares owned by shareholders was adjusted after the market closes on Sunday, March 9th 2025. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

When did Elevai Labs IPO?

Elevai Labs (ELAB) raised $6 million in an initial public offering on Tuesday, November 21st 2023. The company issued 1,500,000 shares at a price of $4.00 per share. Univest Securities acted as the underwriter for the IPO.

How do I buy shares of Elevai Labs?

Shares of ELAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Elevai Labs own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Elevai Labs investors own include BIOLASE (BIOL), Conduit Pharmaceuticals (CDT), Cyclacel Pharmaceuticals (CYCC), Daré Bioscience (DARE), TRACON Pharmaceuticals (TCON), Tempest Therapeutics (TPST) and 22nd Century Group (XXII).

Company Calendar

• Last Earnings: 5/14/2025
• Today: 6/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Multi-Sector Conglomerates
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ELAB
• Previous Symbol: NASDAQ:ELAB
• CIK: 1840563
• Web: elevaiskincare.com
• Phone: 866-794-4940
• Fax: N/A
• Employees: 18
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($433.87)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4.30 million
• Net Margins: -223.41%
• Pretax Margin: -223.37%
• Return on Equity: -124.93%
• Return on Assets: -85.10%

Debt

• Debt-to-Equity Ratio: 0.06
• Current Ratio: 3.86
• Quick Ratio: 3.40

Sales & Book Value

• Annual Sales: $2.45 million
• Price / Sales: 1.21
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $44.17 per share
• Price / Book: 0.05

Miscellaneous

• Outstanding Shares: 1,375,000
• Free Float: 3,033,000
• Market Cap: $2.96 million
• Optionable: N/A
• Beta: -0.95